FDA dramatically narrows use of Johnson & Johnson Covid-19 vaccine

Null

“Our action reflects our updated analysis of the risk of [thrombosis with thrombocytopenia syndrome] following administration of this vaccine and limits the use of the vaccine to certain individuals,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement. “We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic ...

Read Complete Article

Post a Comment

Previous Post Next Post